Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Monday, 27'th Feb 2023
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
02:18pm, Friday, 24'th Feb 2023
Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
02:06pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
01:03pm, Wednesday, 22'nd Feb 2023 GlobeNewswire Inc.
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023
Catalyst Pharmaceutical (CPRX) Stock Moves -1.74%: What You Should Know
10:50pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.25, moving -1.74% from the previous trading session.
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?
05:15pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treat
Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?
02:30pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know
02:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know
10:32am, Wednesday, 15'th Feb 2023
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
12:20pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2
Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know
10:50pm, Monday, 13'th Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.54, moving +0.45% from the previous trading session.
Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why
05:45pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why
02:18pm, Wednesday, 08'th Feb 2023
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
01:03pm, Tuesday, 07'th Feb 2023 GlobeNewswire Inc.
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth
5 Best High Earnings Yield Picks to Grow Your Wealth
12:45pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.
